Safety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper Bottle or A Delivery Device

Phase 3WithdrawnNCT00283764

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Overview

Compare the antihypertensive efficacy of two methods for instilling Xalatan eyedrops

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Conditions

Glaucoma, Open-Angle Ocular Hypertension

Interventions

XalatanDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of primary open angle glaucoma or ocular hypertension in 1 or both eyes Exclusion Criteria: * History of closed/barely open anterior chamber angle or a history of angle closure

Outcomes

Primary Outcomes

Intra-ocular pressure (IOP) level in the study eye.

Secondary Outcomes

Successful eyedrop self-deliveries

Ease of eyedrop administration

Change in safety assessments throughout the study period

Subject preference for the method of drop delivery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.